Expectations trend
FY2028 · fiscal year ending 2028-01-03 · fmp
Silicon Labs (SLAB)
NASDAQInformation TechnologySemiconductorsSnapshot 2026-11-04
$222.00-0.15%
Close 2026-11-04 · 1-day change
NASDAQInformation TechnologySemiconductorsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
4.51 → 4.51 EPS · FY ending Jan 3, 2028 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for SLAB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Gross margin near 63% next quarter | A primary condition in Silicon Labs's published investment case. The stated target is 63%. | Improving | Gross margin falls below 57% next quarter | Gross margin: 61.65% FY2026-Q2; GAAP. Published target: 63%. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 11, 202661.64802 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-01-03 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-oriented semiconductor business still working toward profitability, rather than an established earnings compounder. The long-term thesis is progressing on revenue and margin goals, but the current state is watch, with medium confidence and recent performance below its industry cohort.
The valuation is expensive versus peers, and the expectations gap is modestly positive, suggesting expectations may be ahead of what current results support. The priced-in assessment labels that premium unjustified, though overall fragility is low because the risk factors are not all aligned.
Over the multi-year view, recent results show progress: revenue rose from $178 million to $214 million year over year, gross margin improved, and the operating loss narrowed. Near term, execution remains uncertain because SLAB has missed recent quarters, and a guidance cut is a meaningful risk; confidence in the assessment has also declined to medium.
The thesis depends on growth and margin improvements continuing while the operating loss narrows toward profitability. Near term, a guidance cut would weaken the case, while rate cuts or steadier results and guidance from major technology companies could support the sector backdrop.
For the next 1 to 3 years, SLAB has measurable operating progress but still faces losses, elevated risk, and a valuation that appears expensive relative to peers. The thesis remains under watch and hinges on sustained execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Silicon Labs's published investment case. The stated target is Operating loss less than $17 million. |
| Intact |
| Operating loss worsens beyond $17 million next quarter |
Operating income: $-10.666M FY2026-Q2; GAAP. Published target: Operating loss less than $17 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 11, 2026-10,666,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Partnerships with Texas Instruments and Comminent boost growth | Partnerships with Texas Instruments and Comminent boost growth. | Under Pressure | Partnerships fail to contribute to revenue growth | Qualitative: TI merger delayed (Oct 2026) vs sustained growth target TI merger snag delays growth; Q2 revenue $228M beats expectations; new Austin lab and BG2B chip support innovation. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows to about $207.5 million next quarter | A primary condition in Silicon Labs's published investment case. The stated target is ~$207.5 million. | Intact | Revenue falls below $192 million next quarter | Revenue: $228.189M FY2026-Q2; GAAP. Published target: ~$207.5 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 11, 2026228,189,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 3 quarters. Revenue grew from $178 million in 2025-Q1 to $214 million in 2026-Q1, a 20% increase, with industrial & commercial revenue up 33% in 2026-Q1. Management has consistently emphasized growth and design win momentum, and the financials show delivering progress. Delivery assessment Aug 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$4.43 → $4.51 · observed estimates
$1.08B → $1.08B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-07-25 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-07-26 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-07-27 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-07-28 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-07-29 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-07-30 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-07-31 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-08-01 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-08-02 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-08-03 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-08-04 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-08-05 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-08-06 | $4.43 | $1,075,009,075 | 4 / 5 |
| 2026-08-08 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-09 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-10 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-12 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-13 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-14 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-15 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-16 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-17 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-18 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-19 | $4.43 | $1,075,009,075 | 3 / 4 |
| 2026-08-20 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-21 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-22 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-23 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-24 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-25 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-26 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-27 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-28 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-29 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-30 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-08-31 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-01 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-02 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-03 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-04 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-05 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-06 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-07 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-08 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-09 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-10 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-11 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-12 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-13 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-14 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-15 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-16 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-17 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-18 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-19 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-20 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-21 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-22 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-23 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-24 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-25 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-26 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-27 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-28 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-29 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-09-30 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-01 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-02 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-03 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-04 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-05 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-06 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-07 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-08 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-09 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-10 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-11 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-12 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-13 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-14 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-15 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-16 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-17 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-18 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-19 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-20 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-21 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-22 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-23 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-24 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-25 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-26 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-27 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-28 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-29 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-30 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-10-31 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-11-01 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-11-02 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-11-03 | $4.51 | $1,081,062,220 | 3 / 4 |
| 2026-11-04 | $4.51 | $1,081,062,220 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 8 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.